Company news

Share this article:
Azur Pharma has entered into an agreement with BioSante Pharmaceuticals to acquire US rights to Elestrin, a gel formulation of estradiol indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, for $3.3 million. FDA approved Elestrin in December 2006, and the product is patented through June 2022.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.